3p21 is a recurrent treatment-related breakpoint in myelodysplastic syndrome and acute myeloid leukemia.

@article{Shi19963p21IA,
  title={3p21 is a recurrent treatment-related breakpoint in myelodysplastic syndrome and acute myeloid leukemia.},
  author={Gongyi Shi and Hans Josef Weh and Shelby A. Martensen and Doris Seeger and Dieter Kurt Hossfeld},
  journal={Cytogenetics and cell genetics},
  year={1996},
  volume={74 4},
  pages={
          295-9
        }
}
In this study we report 11 cases with chromosome abnormalities involving 3p21. Nine cases were diagnosed as myelodysplastic syndrome (MDS), and two as acute myeloid leukemia (AML). Six of nine MDS cases were secondary to a primary malignant disease. In two patients, AML was secondary to breast cancer and polycythemia vera (PV). Seven of eleven patients had a history of intensive polychemotherapy and/or radiation therapy for 3.5 to 5 years. The mean interval from initial therapy to secondary… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

Targeting novel signaling pathways for resistant acute myeloid leukemia.

  • Molecular genetics and metabolism
  • 2015
VIEW 3 EXCERPTS
CITES BACKGROUND

t(1;3)(p36;p21): presentation of a patient with MDS/AML (M2) and review of the literature.

  • Turkish journal of haematology : official journal of Turkish Society of Haematology
  • 2006
VIEW 2 EXCERPTS
CITES BACKGROUND